Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug

Fig. 3

Effect of repeated administration of CR6086 on clinical score and oedema in arthritic rats (collagen-induced arthritis [CIA] model). Arthritis was induced by intradermal injection of type II collagen as described in the Methods section of the main text. Three weeks later, animals were boosted. Daily treatments with oral CR6086 started 3 days after boosting and lasted 14 days. Clinical score (a and c) and paw volume (b and d) were assessed 1 h (a and b) and 24 h (c and d) after drug administration. Data represent the mean ± SEM of 12 rats/group. *P < 0.05 vs CIA rats treated with vehicle by two-way repeated measures analysis of variance with Tukey’s multiple comparisons test. ###P < 0.001 CIA vs sham animals at onset (day 0)

Back to article page